FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2310036617> ?p ?o ?g. }

• W2310036617 endingPage "1407" @default.
• W2310036617 startingPage "1398" @default.
• W2310036617 abstract "BACKGROUND The proliferation of clonal cytotoxic T-cells or natural killer cells has been observed after dasatinib treatment in small studies of patients with chronic myeloid leukemia (CML). METHODS The incidence of lymphocytosis and its association with response, survival, and side effects were assessed in patients from 3 large clinical trials. Overall, 1402 dasatinib-treated patients with newly diagnosed CML in chronic phase (CML-CP), CML-CP refractory/intolerant to imatinib, or with CML in accelerated or myeloid-blast phase were analyzed. RESULTS Lymphocytosis developed in 32% to 35% of patients and persisted for >12 months. This was not observed in the patients who received treatment with imatinib. Dasatinib-treated patients in all stages of CML who developed lymphocytosis were more likely to achieve a complete cytogenetic response, and patients who had CML-CP with lymphocytosis were more likely to achieve major and deep molecular responses. Progression-free and overall survival rates were significantly longer in patients with CML-CP who were refractory to or intolerant of imatinib and had lymphocytosis. Pleural effusions developed more commonly in patients with lymphocytosis. CONCLUSIONS Overall, lymphocytosis occurred and persisted in many dasatinib-treated patients in all phases of CML. Its presence was associated with higher response rates, significantly longer response durations, and increased overall survival, suggesting an immunomodulatory effect. Prospective studies are warranted to characterize the functional activity of these cells and to assess whether an immunologic effect against CML is detectable. Cancer 2016;122:1398–1407. © 2016 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society." @default.
• W2310036617 created "2016-06-24" @default.
• W2310036617 creator A5008868111 @default.
• W2310036617 creator A5015115182 @default.
• W2310036617 creator A5015140142 @default.
• W2310036617 creator A5019949455 @default.
• W2310036617 creator A5021092277 @default.
• W2310036617 creator A5029013179 @default.
• W2310036617 creator A5035964802 @default.
• W2310036617 creator A5038582279 @default.
• W2310036617 creator A5050873337 @default.
• W2310036617 date "2016-03-21" @default.
• W2310036617 modified "2023-10-06" @default.
• W2310036617 title "Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity" @default.
• W2310036617 cites W1927479878 @default.
• W2310036617 cites W1973593664 @default.
• W2310036617 cites W1986139301 @default.
• W2310036617 cites W1987060661 @default.
• W2310036617 cites W1990915902 @default.
• W2310036617 cites W1991795177 @default.
• W2310036617 cites W1996544875 @default.
• W2310036617 cites W2000868207 @default.
• W2310036617 cites W2002185737 @default.
• W2310036617 cites W2010109350 @default.
• W2310036617 cites W2023892196 @default.
• W2310036617 cites W2036118441 @default.
• W2310036617 cites W2038161969 @default.
• W2310036617 cites W2050068833 @default.
• W2310036617 cites W2051536771 @default.
• W2310036617 cites W2073035156 @default.
• W2310036617 cites W2078783981 @default.
• W2310036617 cites W2080349789 @default.
• W2310036617 cites W2082751900 @default.
• W2310036617 cites W2084843289 @default.
• W2310036617 cites W2090293697 @default.
• W2310036617 cites W2097799776 @default.
• W2310036617 cites W2106512898 @default.
• W2310036617 cites W2112134874 @default.
• W2310036617 cites W2116153687 @default.
• W2310036617 cites W2124557535 @default.
• W2310036617 cites W2133380474 @default.
• W2310036617 cites W2133697722 @default.
• W2310036617 cites W2158196950 @default.
• W2310036617 cites W2241443122 @default.
• W2310036617 cites W2521948287 @default.
• W2310036617 cites W2534177565 @default.
• W2310036617 cites W2590322037 @default.
• W2310036617 cites W4211076773 @default.
• W2310036617 cites W4230849756 @default.
• W2310036617 doi "https://doi.org/10.1002/cncr.29933" @default.
• W2310036617 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5071708" @default.
• W2310036617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26998677" @default.
• W2310036617 hasPublicationYear "2016" @default.
• W2310036617 type Work @default.
• W2310036617 sameAs 2310036617 @default.
• W2310036617 citedByCount "44" @default.
• W2310036617 countsByYear W23100366172016 @default.
• W2310036617 countsByYear W23100366172017 @default.
• W2310036617 countsByYear W23100366172018 @default.
• W2310036617 countsByYear W23100366172019 @default.
• W2310036617 countsByYear W23100366172020 @default.
• W2310036617 countsByYear W23100366172021 @default.
• W2310036617 countsByYear W23100366172022 @default.
• W2310036617 countsByYear W23100366172023 @default.
• W2310036617 crossrefType "journal-article" @default.
• W2310036617 hasAuthorship W2310036617A5008868111 @default.
• W2310036617 hasAuthorship W2310036617A5015115182 @default.
• W2310036617 hasAuthorship W2310036617A5015140142 @default.
• W2310036617 hasAuthorship W2310036617A5019949455 @default.
• W2310036617 hasAuthorship W2310036617A5021092277 @default.
• W2310036617 hasAuthorship W2310036617A5029013179 @default.
• W2310036617 hasAuthorship W2310036617A5035964802 @default.
• W2310036617 hasAuthorship W2310036617A5038582279 @default.
• W2310036617 hasAuthorship W2310036617A5050873337 @default.
• W2310036617 hasBestOaLocation W23100366171 @default.
• W2310036617 hasConcept C121608353 @default.
• W2310036617 hasConcept C126322002 @default.
• W2310036617 hasConcept C143998085 @default.
• W2310036617 hasConcept C203014093 @default.
• W2310036617 hasConcept C2777583451 @default.
• W2310036617 hasConcept C2777938653 @default.
• W2310036617 hasConcept C2778461978 @default.
• W2310036617 hasConcept C2778729363 @default.
• W2310036617 hasConcept C2779536868 @default.
• W2310036617 hasConcept C2780126324 @default.
• W2310036617 hasConcept C3019892230 @default.
• W2310036617 hasConcept C71924100 @default.
• W2310036617 hasConcept C90924648 @default.
• W2310036617 hasConceptScore W2310036617C121608353 @default.
• W2310036617 hasConceptScore W2310036617C126322002 @default.
• W2310036617 hasConceptScore W2310036617C143998085 @default.
• W2310036617 hasConceptScore W2310036617C203014093 @default.
• W2310036617 hasConceptScore W2310036617C2777583451 @default.
• W2310036617 hasConceptScore W2310036617C2777938653 @default.
• W2310036617 hasConceptScore W2310036617C2778461978 @default.
• W2310036617 hasConceptScore W2310036617C2778729363 @default.
• W2310036617 hasConceptScore W2310036617C2779536868 @default.
• W2310036617 hasConceptScore W2310036617C2780126324 @default.

• next